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The improvement of bioavailability of honokiol, sustained release of 
honokiol and prolongation of half-time were obtained. The inhibition 
of cell proliferation and induced apoptosis of liposomal honokiol were 
time and dose-dependent in in vitro study. The liposomal honokiol 
inhitbited tumor growth in a dose-dependent manner and the antitu-
mor efﬁcacy of liposomal honokiol can be signiﬁcantly enhanced in 
combination with cisplatin. This combination treatment has shown 
marked suppression in tumor growth, prolonged survival and decreased 
microvessel density compared with either treatment alone.
Conclusions: The in vitro and in vivo antitumor effects of liposomal 
honokiol combined with cisplatin indicated that liposomal honokiol can 
be a potential agent as a new sensitizer of anti- lung cancer drug. 
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Background: Oncolytic adenoviruses kill tumor cells by different 
mechanisms from standard anticancer therapies, and synergistic inter-
actions with conventional treatments have been described. However, 
the molecular mechanisms underlying combination-therapy synergy are 
not fully known. 
Methods: We constructed telomerase-speciﬁc replication-competent 
adenovirus (OBP-301: Telomelysin), in which the human telomerase 
reverse transcriptase (hTERT) promoter regulates viral replication. The 
antitumor effects of OBP-301 infection and ionizing radiation were 
evaluated in vitro by XTT assay. Adenovirus infectivity and intracellu-
lar replication were assessed by real-time quantitative PCR. The effects 
of OBP-301 on DNA-protein kinase (PK) catalytic subunit (DNA-
PKcs) expression and nuclear translocation of Ku70/80 were examined 
by western blotting and immunoﬂuorescence staining, respectively. The 
effect of treatment on growth of subcutaneous human tumors trans-
planted into nu/nu mice was compared. 
Results: Post-radiation infection with OBP-301 induced profound in 
vitro cytotoxicity. The virulence of OBP-301 was more efﬁcient after 
radiation, although radiation did not inﬂuence OBP-301 intracellular 
replication rate. OBP-301 infection reduced DNA-PKcs expression in 
A549 human lung cancer cells even after radiation. Ku70/80 protein 
accumulated in nuclei of A549 cells after ionizing radiation but in the 
cytoplasm after OBP-301 infection. Intratumoral injection of OBP-301 
and localized radiation showed a signiﬁcant therapeutic synergism in 
nu/nu mice xenografted with A549 tumor, but OBP-301 and radiation 
induced only modest inhibition of tumor growth when administered 
alone. 
Conclusions: Ionizing radiation and OBP-301 infection mutually 
sensitize tumor cells by increasing viral infectivity and inhibiting DNA 
repair, respectively. This combination therapy efﬁciently enhanced 
antitumor efﬁcacy both in vitro and in vivo. 
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Genetic immunotherapy using tumor vaccine has been tried more than 
a decade without practical impact on clinics. Among several limitations 
of tumor vaccine, low levels of transferred genes, such as cytokines 
and MHC class molecules, are one of major reasons. We previously 
demonstrated that combination gene therapy with conditionally repli-
cating adenovirus (CRAD: Δ24RGD) and adenovirus-p27 induced the 
higher, more extensive and prolonged expression of p27 in human lung 
cancer xenografts and induced the synergistic tumor regression (Cancer 
Research 2006;66:372). Even though this combination of CRAD and 
ad-p27 showed increased expression, the antitumor effects are still 
locoregional. Since cancer is a systemic disease, local treatment effect 
has a limitation for the cure of cancer. Therefore, we have applied the 
combination of CRAD(Δ24) and ad-cytokines (IL-4, GM-CSF and 
IFNβ) in murine lung cancer model (LLC1). Transduction of LLC1 
with Δ24 induced the replication of Δ24, but replication in LLC1 was 
much weaker than that in human lung cancer cell line (NCI H460). 
However, combined transduction of LLC1 with Δ24 and ad-cytokines 
induced stronger and more prolonged expression of cytokine com-
pared with ad-cytokines only (at least 10 times higher expression). It 
means that mutant E1 produced from Δ24 enables the replication of E1 
deleted replication defective adenovirus(ad-cytokines) in tumor when 
cotransduced with both viruses. We performed the in vivo treatment 
experiment by injecting LLC1 transduced in vitro (tumor vaccine) with 
Δ24 only, ad-cyokines only and Δ24 + ad-cytokine, into mice with pre-
established lung cancer(LLC1). Tumor vaccine of Δ24 and ad-cytokine 
more strongly suppressed the growth of preestablished tumor (LLC1) 
compared with other tumor vaccines (Δ24 only and ad-cytokines only). 
These ﬁndings suggest the potential of new tumor vaccine strategy us-
ing combined transduction of CRAD and ad-cytokines. (This study was 
supported by a grant of the Korea Health 21 R&D project, Ministry of 
Health & Welfare, Republic of Korea, A06-00024600)
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Purpose: Poly(ADP-ribose) polymerase-1 (PARP-1) is the founding 
member of a family of enzymes that catalyze the addition of ADP-ri-
bose units to proteins that mediate DNA repair pathways. Ionizing ra-
diation induces DNA strand breaks, suggesting that PARP-1 inhibition 
may sensitize tumor cells to radiation. 
Experimental Design: We investigated the combination of PARP-1 in-
hibition with radiation in lung cancer models. ABT-888, a novel potent 
PARP-1 inhibitor, was used to explore the effects of PARP-1 inhibition 
on irradiated tumors and tumor vasculature.
Results: ABT-888 reduced clonogenic survival in H460 lung cancer 
cells, and inhibited DNA repair as shown by enhanced expression 
of DNA strand break marker histone γ-H2AX. Both apoptosis and 
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autophagy contributed to the mechanism of increased cell death. 
Additionally, ABT-888 increased tumor growth delay at well-toler-
ated doses in murine models. For a 5-fold increase in tumor volume, 
tumor growth delay was 1 day for ABT-888 alone, 7 days for radiation 
alone, and 13.5 days for combination treatment. Immunohistochemical 
staining of tumor sections revealed an increase in TUNEL apoptotic 
staining, and a decrease in Ki-67 proliferative staining after combina-
tion treatment. Matrigel assay showed a decrease in in vitro endothelial 
tubule formation with ABT-888/radiation combination treatment, and 
von Willebrand factor staining of tumor sections revealed decreased 
vessel formation in vivo, suggesting this strategy may also target tumor 
angiogenesis. 
Conclusions: We conclude that PARP-1 inhibition shows promise as 
an effective means of enhancing tumor sensitivity to radiation, and 
future clinical studies are needed to determine the potential of ABT-888 
as a radiation enhancer.
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Antitumour antibodies delivered through airways in lung cancer 
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Effect of nebulization and development of an animal model sensi-
tive to cetuximab
Background: Inhalation is a very attractive and promising route to 
deliver chemotherapy to lung tumours. Indeed, it may increase anti-
tumour responses to drugs by targeting lungs directly and may reduce 
secondary organ toxicity. Although recombinant antitumour antibodies 
are efﬁcient and exciting new therapeutics, they have never been tested 
in lung cancer treatment through airway conduction. Cetuximab, an in-
hibitory anti-EGFR (Epidermal Growth Factor Receptor) antibody, cur-
rently tested in clinical trials for non-small cell lung cancer (NSCLC) 
treatment by i.v. injection, was chosen in that purpose. In this study, we 
evaluated cetuximab nebulization and established an animal model of 
broncho-pulmonary tumour sensitive to this antibody. 
Methods: Cetuximab was nebulized with IA-1C MicroSprayer™ 
(PennCentury Inc., USA) connected to a FMJ-250 high pressure 
syringe (PennCentury Inc., USA), a device used to administrate aerosol 
in mice. The effect of nebulization on cetuximab was assessed in terms 
of its afﬁnity for membrane EGFR (using ﬂow cytometry), inhibition 
of cell growth and inhibition of EGFR phosphorylation. Tolerance to 
cetuximab delivered through airways was studied in mice. Cetuximab 
was injected either by i.p. bi-weekly (1mg) or by endotracheal spray 
using MicroSprayer™ once a week (1mg or 2.125mg). The mice were 
observed bi-weekly and monitored for signs of wound healing distur-
bance, and organ toxicity was determined post-mortem. To establish an 
animal model, we chose A431 cells, a line sensitive to EGFR inhibitors 
and used as reference in cetuximab studies. For intrabronchial tumour 
implantation, A431 cells (2 or 5. 106 cells) were injected endotrache-
ally with or without EDTA (10mM) or BDTM PuraMatrixTM Peptide 
Hydrogel in nude mice. After 6 weeks, mice were sacriﬁed and the 
number of tumour nodules in lungs was determined by histological 
examination.
Results: Firstly, our results showed that MicroSprayer™ did not alter 
cetuximab integrity, immunological and pharmacologic properties. 
Secondly, airway administration of cetuximab in mice seemed to be 
well-tolerated and did not induced additional toxicity in lungs, kidney, 
colon, skin, liver or spleen. Finally, addition of EDTA seemed critical 
for A431 tumour implantation in lungs.
Conclusion: The validation of our experimental system will allow us 
to compare cetuximab antitumour response by systemic and inhaled 
routes; and thus, to deﬁne the potential of aerosol for antitumour anti-
body administration in NSCLC.
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Activity and mechanism of action of motexafin gadolinium in lung 
cancer: Involvement of NRF-2 transcription factor antioxidant 
response
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Background: Motexaﬁn gadolinium (MGd, Xcytrin®) is a tumor-selec-
tive anti-cancer agent that oxidizes intracellular reducing metabolites 
to generate reactive oxygen species (ROS). MGd was found to prolong 
time to neurologic progression in patients with brain metastases from 
non-small cell lung cancer (NSCLC) in a randomized trial comparing 
whole brain radiation (WBRT) plus MGd to WBRT alone. Single agent 
anti-tumor activity has been seen in several ongoing phase 1 and 2 tri-
als including NSCLC.
Methods: A549 human lung cancer cell line was used for these 
experiments. Cells were cultured in medium with or without glucose. 
Mitochondrial DNA deﬁcient A549 cells were prepared by passaging in 
medium containing ethidium bromide. Free intracellular zinc was mea-
sured using FluoZin-3™ and ﬂow cytometry. A lipoate reduction assay 
was used to determine effect on cellular bioreductive capacity, which is 
known to be affected by redox stress and zinc levels. Cellular respira-
tion was measured using a Clark electrode (Oxytherm™). Knockdown 
of antioxidant enzymes was obtained by transient transfection with 
small hairpin RNA sequences complementary to the target RNA. 
Results: In vitro treatment with MGd and physiologically relevant 
levels of zinc led to synergistic increases of free intracellular zinc 
levels and cytotoxicity. MGd cytotoxicity was found to be increased by 
using spent medium or medium deﬁcient in glutamine and or glucose 
suggesting disruption of metabolism. MGd and zinc inhibited the biore-
ductive capacity of cells as measured by effects on reduction of lipoate. 
These effects were further potentiated by mitochondrial inhibitors, 
under hypoxic conditions, and in A549 cells deﬁcient in mitochondrial 
DNA. In these cells, exposure to 10 μM MGd led to a 2.5 fold increase 
in intracellular free Zn measured by FluoZin-3 ﬂuorescence after 4 
hr. A549 cell oxygen consumption was decreased by 20% in spent 
medium after 18 hr treatment. Knockdown of the NRF-2 transcription 
factor, which controls cellular response to oxidative stress, led to 50% 
decrease in protein levels of thioredoxin reductase 1 and glutathione 
reductase. MGd and zinc treatment inhibited bioreductive capacity to 
a greater degree following NRF-2 knockdown as compared to control, 
non-targeting shRNA.
Conclusions: NRF-2 antioxidant response has been reported to be 
associated with poor prognosis and resistance to therapy in NSCLC. 
MGd is a redox cycling anti-cancer agent that causes redox stress 
